Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
Pietro De Placido(University of Naples Federico II), Grazia Arpino(University of Naples Federico II), Margherita Tafuro(University of Naples Federico II), Anna Iervolino(University of Campania "Luigi Vanvitelli"), Carmine De Angelis(Baylor College of Medicine), Roberto Buonaiuto(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Mario Giuliano(Regione Campania), Rosa Giannatiempo, Erica Pietroluongo(University of Naples Federico II), Chiara Barraco(University of Naples Federico II), Emilia Anna Vozzella(Federico II University Hospital), Francesco Schettini(Target (United States))
Cited by 11
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273